Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06411821 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ulixertinib in People With Histiocytic Neoplasms

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 39 words
  2. Eligibility criteria expanded, about 14 wordsv8
  3. Eligibility criteria expanded, about 9 wordsv7
  4. Re-verified, no change to tracked fieldsv6
  5. Study sites: 7 to 8v5
  6. 3 versions Re-verified since May 13, 2024, no change to tracked fieldsv2-v4
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The researchers are doing this study is to find out whether ulixertinib is an effective and safe treatment for people with histiocytic neoplasms.
Trial Details
NCT Number NCT06411821
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: BioMed Valley Discoveries, Inc
Conditions
(from sponsor)		 Histiocytic Neoplasms
Enrollment 38 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov